Aripiprazole in Pregnancy
The metabolic "green zone" of the SGAs — lowest gestational-diabetes risk of any — but with three features unique to a D₂ partial agonist: a neurodevelopmental signal, a vanishing serum level, and a real threat to lactation.
⏱ The 30-Second Review — for busy clinicians
- The metabolic standout. Among the lowest GDM risk of any SGA (aRR 0.82; below 1.0, alongside ziprasidone at 0.76), low weight gain, low sedation. The preferred agent when metabolic risk dominates.
- The neurodevelopmental signal. Aripiprazole was the lone individual agent with a persistent NDD signal in the largest US cohort (any-NDD aHR 1.36) — but it was inconsistent across analyses and confounding by indication (MDD augmentation) couldn't be excluded, and no study has replicated it. Disclose it; don't let it alone drive avoidance.
- The vanishing dose. Serum levels fall 52–77% by the third trimester — second only to quetiapine. A decompensating patient in T2/T3 is more likely running low than non-adherent. PBPK suggests roughly doubling the dose; use TDM where available.
- The lactation threat. Uniquely among antipsychotics, aripiprazole lowers prolactin. One postpartum cohort found 74% complete lactation failure. If breastfeeding matters, plan for it now.
- Akathisia. Its signature side effect (up to ~25% in MDD-adjunct use) and easily mistaken for anxiety in pregnancy. Think akathisia before adding an anxiolytic.
The Bottom Line
Aripiprazole is a second-generation antipsychotic with a distinctive profile — a D₂ partial agonist and 5-HT1A partial agonist — approved for schizophrenia, bipolar I disorder, adjunctive MDD, irritability in autism, and Tourette's.1 Published epidemiologic studies have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal outcomes.1 Its signature advantage in pregnancy is metabolic: the Medicaid cohort found an adjusted GDM risk ratio of 0.82 (95% CI 0.50–1.33) — among the lowest of any SGA and one of only two with a point estimate below 1.0 (alongside ziprasidone, aRR 0.76; neither significant),2 with the Swedish register confirming that "other SGAs" (including aripiprazole) carried no excess metabolic risk.3
Three features set it apart. First, a possible neurodevelopmental signal (any-NDD aHR 1.36; 95% CI 1.14–1.63) that was inconsistent across analyses and could not exclude confounding by indication.4 Second, a unique lactation risk: because it suppresses prolactin, the FDA label warns of decreased milk supply, and a recent cohort found 74% complete lactation failure among women continuing it postpartum.5618 Third, a 52–77% decline in serum levels by the third trimester, often requiring dose adjustment.78
Reproductive Safety & Teratogenicity
Aripiprazole has a growing but still moderate-sized database — smaller than quetiapine's or olanzapine's.
National Pregnancy Registry (Freeman 2021). 158 women with first-trimester aripiprazole exposure vs 690 controls. Major malformations occurred in 4.29% (7/163 infants) of exposed vs 1.99% (14/690) of controls; the unadjusted OR was 2.21 (95% CI 0.88–5.57), but after adjustment the OR was 1.35 (95% CI 0.43–4.20) — not significant. The authors called the results reassuring but limited by small numbers.9
Huybrechts 2016 Medicaid cohort (~1.36M pregnancies; malformation study). Atypicals as a class showed no increased malformation risk after adjustment (aRR 1.05; 95% CI 0.96–1.16); aripiprazole specifically was not associated, and the only persistent individual signal was risperidone.10
Huybrechts 2023 multinational cohort. After propensity-score adjustment, most antipsychotic–malformation estimates moved toward the null (range ~0.7–1.2 for combinations with substantial information); the only exception was olanzapine and oral clefts. Aripiprazole showed no specific signal.11
Network meta-analysis (Wang 2025). Among 22 studies (3,042,997 pregnancies), aripiprazole's OR was 1.30 (95% CrI 1.10–1.65) — above quetiapine (1.19), below olanzapine (1.33), risperidone (1.43), and lithium (1.61).12
French prospective cohort (Bellet 2015). In 86 exposed vs 172 matched controls, aripiprazole was not significantly associated with malformations (OR 2.30; 95% CI 0.32–16.7) or GDM (OR 1.15; 95% CI 0.33–4.04), but showed increased prematurity (OR 2.57; 95% CI 1.06–6.27) and fetal growth retardation (OR 2.97; 95% CI 1.23–7.16) — findings the authors flagged as hard to interpret given short exposure and confounding.13
FDA label. Published data have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal outcomes. In animals, aripiprazole at ~10× (rats) and ~19× (rabbits) the MRHD produced fetal death, decreased fetal weight, undescended testicles, delayed skeletal ossification, skeletal abnormalities, and diaphragmatic hernia.1
Aripiprazole's malformation data are reassuring but less robust than quetiapine's. The MGH registry had only 158 exposed women (vs 152 for quetiapine), and the unadjusted 4.29% rate exceeded controls — though it lost significance after adjustment.9 The French cohort's prematurity/growth-retardation signal has not been replicated.13 Counsel aripiprazole as "not established as a teratogen," with a profile comparable to other SGAs but a smaller evidence base than quetiapine.
Fetal & Neonatal Risks
A. Neonatal Adaptation (EPS / Withdrawal)
Third-trimester exposure carries risk of neonatal extrapyramidal and/or withdrawal symptoms — agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder. Severity varies; some neonates recover within hours to days without treatment, others need prolonged hospitalization.1
As a D₂ partial agonist, aripiprazole's neonatal-adaptation profile is pharmacologically distinct from full D₂ antagonists (risperidone → more hypertonia/tremor) and low-D₂ agents (quetiapine → more sedation/hypotonia); the presentation may blend both. A small Australian multicenter study (26 women) noted higher-than-expected neonatal admission rates.14
B. Fetal Growth
Unlike olanzapine and quetiapine, aripiprazole sits among the non-high-metabolic-risk SGAs. The Swedish register found "other SGAs" (including aripiprazole) were not associated with LGA infants or GDM.3 The French cohort, however, found increased fetal growth retardation (OR 2.97; 95% CI 1.23–7.16) — the opposite direction from the macrosomia concern with the high-metabolic agents — unreplicated and possibly confounded.13
Where olanzapine and quetiapine push toward LGA via maternal metabolic effects, aripiprazole may carry a small risk in the opposite direction — growth retardation — based on a single French cohort.13 This is unconfirmed and may reflect confounding by illness severity (poorer nutrition, higher smoking). The standard 20-week anatomy scan suffices; serial growth ultrasounds are not routinely indicated for aripiprazole absent other risk factors.
Neurodevelopmental Outcomes — the Signal
Aripiprazole is the only individual antipsychotic with a persistent (though unconfirmed) neurodevelopmental signal in the largest US cohort.
In ~3.35 million children with up to 14 years' follow-up, antipsychotics as a class showed no substantial NDD risk after adjustment (pooled aHR 1.08; 95% CI 1.01–1.17). Aripiprazole was the exception: children exposed in the second half of pregnancy had increased risks of any NDD (aHR 1.36; 95% CI 1.14–1.63), speech/language disorder (aHR 1.61; 95% CI 1.28–2.02), and behavioral disorder (aHR 1.63; 95% CI 1.18–2.26). The authors stated that post-hoc analyses could not rule out causality.4
Interpretation. The authors and later commentators stressed that the signal was inconsistent across analyses and that confounding by maternal illness was not excluded. Aripiprazole is increasingly used for MDD augmentation — a population that may differ systematically (more comorbid anxiety, different socioeconomic factors). The 2026 systematic review concluded that, after confounder adjustment, school-age NDD risk does not appear increased for antipsychotics as a class, while acknowledging the aripiprazole-specific signal needs further study.1516
The most nuanced counseling point for aripiprazole. The signal is real (significant in the largest study) but unconfirmed and plausibly confounded. Key points: (1) for antipsychotics as a class, the apparent NDD risk disappears after adjusting for maternal characteristics — the illness, not the drug, drives it; (2) aripiprazole is the lone exception with a persistent signal; (3) it was inconsistent across sensitivity analyses, and confounding by indication (its unique MDD-augmentation use) is a live explanation; (4) no other study has replicated it.415 Disclose it transparently — but don't let it be the sole reason to avoid aripiprazole if it is the best agent for the patient.
Metabolic Profile & Akathisia
Aripiprazole has the most favorable metabolic profile among commonly used SGAs in pregnancy — its central advantage.
| Risk Factor | Aripiprazole Level | Comparison to Other SGAs | Clinical Action |
|---|---|---|---|
| Gestational diabetes | Among lowest aRR 0.82 | Below quetiapine (1.28), risperidone (1.09), olanzapine (1.61); comparable to ziprasidone (0.76) | Standard GDM screen 24–28 wks; no early screen unless other risk factors |
| Weight gain | Low | Below olanzapine/quetiapine; comparable to ziprasidone | Standard prenatal weight monitoring |
| LGA infant | Not elevated | Not in the high-metabolic group (unlike OLZ/CLZ/QTP) | Standard growth monitoring |
| Sedation | Low | Much lower than quetiapine or olanzapine | Can dose in the morning; less fall risk |
| Akathisia | High 8–25% by indication | Higher than other SGAs | Monitor for restlessness; distinguish from anxiety; consider dose ↓ or propranolol |
| Prolactin | Lowers it | Only SGA that lowers prolactin | Counsel re: possible lactation failure (Section 5) |
The Medicaid cohort (1,924 aripiprazole-exposed) found a crude GDM rate of 4.8% in continuers vs 4.5% in discontinuers (aRR 0.82; 95% CI 0.50–1.33) — among the lowest of any SGA, one of only two agents with a point estimate below 1.0 (ziprasidone was lower still at aRR 0.76 [95% CI 0.29–2.00], though neither reached significance).2 Its most clinically significant side effect in pregnancy is akathisia; the label lists incidence varying by indication (≈8% schizophrenia, ≈13% bipolar mania, ≈25% MDD adjunct).1
Aripiprazole-induced akathisia is easy to miss in pregnancy: anxiety is already common, the restlessness can mimic or worsen it, and patients may not recognize the motor component. If a pregnant patient on aripiprazole reports worsening "anxiety" or inability to relax, consider akathisia before adding an anxiolytic. A brief dose reduction or low-dose propranolol (generally safe in pregnancy) can be both diagnostic and therapeutic.
The Prolactin–Lactation Issue
This is aripiprazole's most distinctive perinatal consideration and warrants prominent discussion.
The pharmacology. As a D₂ partial agonist, at the pituitary — where tonic dopamine inhibits prolactin release — aripiprazole functionally suppresses prolactin secretion, often pushing levels below normal. This is the opposite of all other antipsychotics, which raise prolactin.17
The label warns that aripiprazole exposure during pregnancy and/or postpartum can lead to variable effects on milk supply, including clinically relevant decreases that may be reversible on discontinuation — with reports of no maternal milk supply postpartum — likely mediated through decreased prolactin.6 A 2025 perinatal-psychiatry cohort (Nanjundaswamy; 35 women continuing aripiprazole through pregnancy and postpartum) found 74% (26/35) complete lactation failure and 11% (4/35) insufficient milk; mean dose 16.4 mg/day. Separate case reports and small series have likewise described impaired milk production with aripiprazole, with a possible dose relationship.5
The lactation data for aripiprazole are the most concerning of any SGA; a 74% complete-failure rate must be discussed with any patient who plans to breastfeed,5 and the label confirms the prolactin-mediated mechanism.6 Three options: (1) if breastfeeding is a high priority, consider switching to a prolactin-neutral or prolactin-raising agent (e.g., quetiapine) before delivery — only if the switch is safe; (2) if aripiprazole is the only effective agent, counsel that breastfeeding may not be possible and have a formula plan ready; (3) some clinicians reduce the dose in the final weeks to allow prolactin recovery, but this is not evidence-based and carries relapse risk. Individualize — maternal stability versus breastfeeding goals.
Pharmacokinetics & Clinic-Ready Tools
The Vanishing Dose
- Metabolism. Primarily CYP2D6 and CYP3A4; the active metabolite dehydro-aripiprazole is ~40% of aripiprazole AUC at steady state. In pregnancy, CYP3A4 activity rises substantially (up to ~2.3-fold by T3) while CYP2D6 stays relatively stable or modestly rises.119
- Serum decline (TDM). The Norwegian study found aripiprazole concentrations fell 52% in the third trimester (95% CI −62% to −39%; p < 0.001) — second only to quetiapine (−76%) among SGAs.7
- PBPK modeling. Active-moiety AUC fell 12.6%, 38.8%, and 60.9% across the three trimesters; third-trimester levels were "entirely unable to reach" the effective concentration (150 ng/mL). The authors recommended late-pregnancy doses of at least 2× baseline.20
- 2026 systematic review. Reported declines up to ~76.8% in the third trimester — even larger than the Norwegian estimate.8
- Placental transfer. Mean ratio ~56% (from limited case-level data) — intermediate between quetiapine (~24%) and olanzapine (~72%).2122
Aripiprazole's serum-level decline is among the largest of the SGAs — second only to quetiapine on direct TDM measurement (−52% vs −76%), though the two converge at the extremes, with systematic-review upper estimates for aripiprazole (~76.8%) overlapping quetiapine's (~76.2%).78 Unlike olanzapine (stable at −9%), it requires active dose management. If a previously stable patient decompensates in T2/T3, declining drug levels should be the first consideration — not non-adherence or disease progression. Use TDM where available; PBPK suggests doses may need to roughly double by T3.20 The moderate placental ratio (~56%) means fetal exposure rises proportionally with dose increases but stays intermediate.21
Patient Script — Using Aripiprazole During Pregnancy
"Aripiprazole is one of our best options for keeping your weight and blood sugar healthy during pregnancy. Unlike some other medicines in this class, it doesn't increase your risk of pregnancy diabetes — that's a real advantage.
The largest studies haven't found it to cause birth defects. A few things to plan for, though. First, your body clears this medicine faster during pregnancy, so we may need to raise your dose as you go to keep it working — we'll watch closely. Second, it can sometimes make it harder to produce breast milk after delivery, so if breastfeeding is important to you, let's talk about that now and make a plan. And like all medicines in this class, there's a small chance the baby is a little jittery or restless for a few days after birth — temporary, and the pediatric team knows how to handle it."
EMR Documentation Template
Quick Reference
Preconception / Early
Reasonable choice when metabolic risk dominates. Disclose NDD signal and lactation risk; establish breastfeeding plan early.
Antepartum
Standard GDM screen 24–28 wks. Watch for akathisia. Anticipate dose increase in T2/T3; TDM where available.
Delivery / Postpartum
Neonatal EPS/withdrawal watch. Expect possible lactation failure — formula plan ready; monitor infant feeding/weight.
National Pregnancy Registry for Atypical Antipsychotics (MGH) monitors outcomes for atypical antipsychotics including aripiprazole. Providers can register patients: 1-866-961-2388 or womensmentalhealth.org.1
References
- Aripiprazole (ABILIFY) US prescribing information. US Food and Drug Administration.
- Park Y, Hernandez-Diaz S, Bateman BT, et al. Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry. 2018;175(6):564–574. doi:10.1176/appi.ajp.2018.17040393
- Heinonen E, Forsberg L, Nörby U, Wide K, Källén K. Antipsychotic use during pregnancy and risk for gestational diabetes: a national register-based cohort study in Sweden. CNS Drugs. 2022;36(5):529–539. doi:10.1007/s40263-022-00908-2
- Straub L, Hernández-Díaz S, Bateman BT, et al. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: a national birth cohort study. JAMA Intern Med. 2022;182(5):522–533. doi:10.1001/jamainternmed.2022.0375
- Nanjundaswamy MH, Shah A, Lotlikar S, et al. Lactation-related side effects of aripiprazole: a study from perinatal psychiatry services in India. J Clin Psychopharmacol. 2025;45(3):258–266. doi:10.1097/JCP.0000000000001997
- Aripiprazole. US Food and Drug Administration prescribing information (lactation section).
- Westin AA, Brekke M, Molden E, et al. Treatment with antipsychotics in pregnancy: changes in drug disposition. Clin Pharmacol Ther. 2018;103(3):477–484. doi:10.1002/cpt.770
- Adhayanti I, Robiyanto R, Bahar MA, Wahyudin E. Trimesters-induced changes in pharmacokinetic parameters of antipsychotics. Arch Womens Ment Health. 2026;29(1):16. doi:10.1007/s00737-025-01665-z
- Freeman MP, Viguera AC, Góez-Mogollón L, et al. Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Arch Womens Ment Health. 2021;24(4):659–667. doi:10.1007/s00737-021-01115-6
- Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–946. doi:10.1001/jamapsychiatry.2016.1520
- Huybrechts KF, Straub L, Karlsson P, et al. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US. JAMA Psychiatry. 2023;80(2):156–166. doi:10.1001/jamapsychiatry.2022.4109
- Wang E, Liu Y, Wang Y, et al. Comparative safety of antipsychotic medications and mood stabilizers during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. CNS Drugs. 2025;39(1):1–22. doi:10.1007/s40263-024-01131-x
- Bellet F, Beyens MN, Bernard N, et al. Exposure to aripiprazole during embryogenesis: a prospective multicenter cohort study. Pharmacoepidemiol Drug Saf. 2015;24(4):368–380. doi:10.1002/pds.3749
- Galbally M, Frayne J, Watson SJ, Snellen M. Aripiprazole and pregnancy: a retrospective, multicentre study. J Affect Disord. 2018;238:593–596. doi:10.1016/j.jad.2018.06.004
- Kaplan CA, Poels EMP, van den Heuvel MI, et al. Systematic review: antipsychotic medication in pregnancy and neurodevelopmental outcomes in children. J Am Acad Child Adolesc Psychiatry. 2026;65(3):354–368. doi:10.1016/j.jaac.2025.04.008
- Andrade C. Attention-deficit/hyperactivity disorder, autism spectrum disorder, and other neurodevelopmental outcomes associated with antipsychotic drug exposure during pregnancy. J Clin Psychiatry. 2022;83(3):22f14529. doi:10.4088/JCP.22f14529
- Aripiprazole pituitary D₂ partial agonism and prolactin lowering — see product labeling and pharmacology references. (Mechanistic; see r1.)
- Aripiprazole. US Food and Drug Administration prescribing information (effects on lactation/milk supply).
- Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G. Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach. Clin Pharmacokinet. 2021;60(12):1569–1582. doi:10.1007/s40262-021-01041-x
- Zheng L, Tang S, Tang R, et al. Dose adjustment of quetiapine and aripiprazole for pregnant women using physiologically based pharmacokinetic modeling and simulation. Clin Pharmacokinet. 2021;60(5):623–635. doi:10.1007/s40262-020-00962-3
- Windhager E, Kim SW, Saria A, et al. Perinatal use of aripiprazole: plasma levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol. 2014;34(5):637–641. doi:10.1097/JCP.0000000000000171
- Schoretsanitis G, Westin AA, Deligiannidis KM, Spigset O, Paulzen M. Excretion of antipsychotics into the amniotic fluid, umbilical cord blood, and breast milk: a systematic critical review and combined analysis. Ther Drug Monit. 2020;42(2):245–254. doi:10.1097/FTD.0000000000000692
Responses